Tamoxifen - DEBIO 1143 kombinasyonunun östrojen reseptörü pozitif meme kanseri hücre hatlarındaki etkisi.

Abstract

Purpose: To investigate the effect of increased concentrations of Tamoxifen (TAM) and DEBIO 1143 (AT-406) administered alone or in combination on cells in MCF-7 and BT-474 estrogen receptor positive (ER +) breast cancer cell lines. Materials and Methods: The effect of Tamoxifen and DEBIO 1143 administered alone or in combination on cell viability in MCF-7 and BT-474 cell lines at the 72nd hour was assessed by the XTT test. Multi-parameter apoptosis assay kit was used to display the effect of the alone/combination of TAM and DEBIO 1143 on both cell lines. Fluorescence microscobic analysis was performed. Results: The IC 50 value of TAM was 3.8±0.6 micromolar (µM) and 18.9±6.7 µM in the MCF-7 and BT-474 cell lines, respectively. The IC 50 value of DEBIO 1143 was 15±0.5 µM in the MCF-7 cell line. The results related to drug combination were statistically significant for both cell lines ( p< 0.001). The decrease in cell viability was not associated with apoptosis. Conclusion: In ER + breast cancer cell lines, the combined doses of the TAM and DEBIO 1143 reduced cell viability more than their administration alone. Combined administrations in both cell lines were concluded in a synergistic effect. Further research is needed to determine which cell death type other than apoptosis is associated with a reduction in cell viability caused by combined administration.